The effects of all psychoactive drugs occur through their interactions with our endogenous neurotransmitter systems. Many of these drugs, and their relationships, are shown in Figure \(\PageIndex{1}\). As you have learned, drugs can act as agonists or antagonists of a given neurotransmitter system. An agonist facilitates the activity of a neurotransmitter system, and antagonists impede neurotransmitter activity.
Figure \(\PageIndex{1}\): various drug categories and the overlap among them. [This work, “Overlapping Drug Categories,” is licensed under CC BY-NC-SA 4.0 by Judy Schmitt. It is a derivative of “Drug Chart version 1.0” by Derek Snider/Wikimedia Commons, which is licensed under CC BY 1.0.]
Alcohol and Other Depressants
Ethanol, which we commonly refer to as alcohol, is in a class of psychoactive drugs known as depressants (Figure \(\PageIndex{2}\)). A depressant is a drug that tends to suppress central nervous system activity. Other depressants include barbiturates and benzodiazepines. These drugs share in common their ability to serve as agonists of the gamma-aminobutyric acid (GABA) neurotransmitter system. Because GABA has a quieting effect on the brain, GABA agonists also have a quieting effect; these types of drugs are often prescribed to treat both anxiety and insomnia.
Figure \(\PageIndex{2}\): The GABA-gated chloride (Cl−) channel is embedded in the cell membrane of certain neurons. The channel has multiple receptor sites where alcohol, barbiturates, and benzodiazepines bind to exert their effects. The binding of these molecules opens the chloride channel, allowing negatively charged chloride ions (Cl−) into the neuron’s cell body. Changing its charge in a negative direction pushes the neuron away from firing; thus, activating a GABA neuron has a quieting effect on the brain. [“Figure 4.17” by CNX OpenStax is licensed under CC BY 4.0.]
Acute alcohol administration results in a variety of changes to consciousness. At rather low doses, alcohol use is associated with feelings of euphoria. As the dose increases, people report feeling sedated. Generally, alcohol is associated with decreases in reaction time and visual acuity, lowered levels of alertness, and reduction in behavioral control. With excessive alcohol use, a person might experience a complete loss of consciousness and/or difficulty remembering events that occurred during a period of intoxication (McKim & Hancock, 2013). In addition, if a pregnant woman consumes alcohol, her infant may be born with a cluster of birth defects and symptoms collectively called fetal alcohol spectrum disorder (FASD) or fetal alcohol syndrome (FAS).
With repeated use of many central nervous system depressants, such as alcohol, a person becomes physically dependent upon the substance and will exhibit signs of both tolerance and withdrawal. Psychological dependence on these drugs is also possible. Therefore, the abuse potential of central nervous system depressants is relatively high.
Drug withdrawal is usually an aversive experience, and it can be a life-threatening process in individuals who have a long history of very high doses of alcohol and/or barbiturates. This is of such concern that people who are trying to over- come addiction to these substances should only do so under medical supervision.
Stimulants
Stimulants are drugs that tend to increase overall levels of neural activity. Many of these drugs act as agonists of the dopamine neurotransmitter system. Dopamine activity is often associated with reward and craving; therefore, drugs that affect dopamine neurotransmission often have abuse liability. Drugs in this category include cocaine, amphetamines (including methamphetamine), cathinones (i.e., bath salts), MDMA (ecstasy), nicotine, and caffeine.
Cocaine can be taken in multiple ways. While many users snort cocaine, intravenous injection and ingestion are also common. The freebase version of cocaine, known as crack, is a potent, smokable version of the drug. Like many other stimulants, cocaine agonizes the dopamine neurotransmitter system by blocking the reuptake of dopamine in the neuronal synapse.
LINK TO LEARNING
Read this interesting newspaper article describing myths about crack cocaine.
Amphetamines have a mechanism of action quite similar to cocaine in that they block the reuptake of dopamine in addition to stimulating its release (Figure \(\PageIndex{3}\)). While amphetamines are often abused, they are also commonly pre- scribed to children diagnosed with attention deficit hyperactivity disorder (ADHD). It may seem counterintuitive that stimulant medications are prescribed to treat a disorder that involves hyperactivity, but the therapeutic effect comes from increases in neurotransmitter activity within certain areas of the brain associated with impulse control.
Figure \(\PageIndex{3}\): As one of their mechanisms of action, cocaine and amphetamines block the reuptake of dopamine from the synapse into the presynaptic cell. [“Figure 4.19” by CNX OpenStax is licensed under CC BY 4.0.]
DIG BEEPER
Crack Cocaine
Crack (Figure \(\PageIndex{4}\)) is often considered to be more addictive than cocaine itself because it is smokable and reaches the brain very quickly. Crack is often less expensive than other forms of cocaine; therefore, it tends to be a more accessible drug for individuals from impoverished segments of society. During the 1980s, many drug laws were rewritten to punish crack users more severely than cocaine users. This led to discriminatory sentencing with low-income, inner-city minority populations receiving the harshest punishments. The wisdom of these laws has recently been called into question, especially given research that suggests crack may not be more addictive than other forms of cocaine, as previously thought (Haasen & krausz, 2001; Reinerman, 2007). ■
Figure \(\PageIndex{4}\): Crack rocks like these are smoked to achieve a high. Compared with other routes of administration, smoking a drug allows it to enter the brain more rapidly, which can often enhance the user’s experience. [“Rocks of crack cocaine” by Drug Enforcement Administration/Wikimedia Commons is in the public domain.)
In recent years, methamphetamine (meth) use has become increasingly widespread. Methamphetamine is a type of amphetamine that can be made from ingredients that are readily available (e.g., medications containing pseudoephedrine, a compound found in many over-the-counter cold and flu remedies). Despite recent changes in laws designed to make obtaining pseudoephedrine more difficult, methamphetamine continues to be an easily accessible and relatively inexpensive drug option (Shukla et al., 2012).
Users of cocaine, amphetamine, cathinones, and MDMA seek a euphoric high—feelings of intense elation and plea- sure—especially those who take the drug via intravenous injection or smoking. Repeated use of these stimulants can have significant adverse consequences. Users can experience physical symptoms that include nausea, elevated blood pressure, and increased heart rate. In addition, these drugs can cause feelings of anxiety, hallucinations, and paranoia (Fiorentini et al., 2011). Normal brain functioning is altered after repeated use of these drugs. For example, repeated use can lead to over- all depletion among the monoamine neurotransmitters (dopamine, norepinephrine, and serotonin). People may engage in compulsive use of these stimulant substances in part to try to reestablish normal levels of these neurotransmitters (Jayanthi & Ramamoorthy, 2005; Rothman et al., 2007).
Caffeine is another stimulant drug. While it is probably the most commonly used drug in the world, the potency of this particular drug pales in comparison to the other stimulant drugs described in this section. Generally, people use caffeine to maintain increased levels of alertness and arousal. Caffeine is found in many common medicines (such as weight loss drugs), beverages, foods, and even cosmetics (Herman & Herman, 2013). While caffeine may have some indirect effects on dopamine neurotransmission, its primary mechanism of action involves antagonizing adenosine activity (Porkka-Heiskanen, 2011).
While caffeine is generally considered a relatively safe drug, high blood levels of caffeine can result in insomnia, agitation, muscle twitching, nausea, irregular heartbeat, and even death (Reissig et al., 2009; Wolk et al., 2012). In 2012, Kromann and Nielson reported on a case study of a 40-year- old woman who suffered significant ill effects from her use of caffeine. The woman had used caffeine in the past to boost her mood and to provide energy, but over the course of several years, she increased her caffeine consumption to the point that she was consuming three liters of soda each day. Although she had been taking a prescription antidepressant, her symptoms of depression continued to worsen and she began to suffer physically, displaying significant warning signs of cardiovascular disease and diabetes. Upon admission to an outpatient clinic for treatment of mood disorders, she met all of the diagnostic criteria for substance dependence and was advised to dramatically limit her caffeine intake. Once she was able to limit her use to less than 12 ounces of soda a day, both her mental and physical health gradually improved. Despite the prevalence of caffeine use and the large number of people who confess to suffering from caffeine addiction, this was the first published description of soda dependence appearing in scientific literature.
Nicotine is highly addictive, and the use of tobacco products is associated with increased risks of heart disease, stroke, and a variety of cancers. Nicotine exerts its effects through its interaction with acetylcholine receptors. Acetylcholine functions as a neurotransmitter in motor neurons. In the central nervous system, it plays a role in arousal and reward mechanisms. Nicotine is most commonly used in the form of tobacco products like cigarettes or chewing tobacco; there- fore, there is a tremendous interest in developing effective smoking cessation techniques. To date, people have used a variety of nicotine replacement therapies in addition to various psychotherapeutic options in an attempt to discontinue their use of tobacco products. In general, smoking cessation programs may be effective in the short term, but it is unclear whether these effects persist (Cropley et al., 2008; Levitt et al., 2007; Smedslund et al., 2004).
Opioids
An opioid is one of a category of drugs that includes heroin, morphine, methadone, and codeine. Opioids have analgesic properties; that is, they decrease pain. Humans have an endogenous opioid neurotransmitter system—the body makes small quantities of opioid compounds that bind to opioid receptors, reducing pain and producing euphoria. Thus, opioid drugs, which mimic this endogenous painkilling mechanism, have an extremely high potential for abuse. Natural opioids, called opiates, are derivatives of opium, which is a naturally occur- ring compound found in the poppy plant. There are now several synthetic versions of opiate drugs (correctly called opioids) that have very potent painkilling effects, and they are often abused. For example, the National Institutes of Drug Abuse has sponsored research that suggests the misuse and abuse of the prescription pain killers hydrocodone and oxycodone are significant public health concerns (Maxwell, 2006). In 2013, the U.S. Food and Drug Administration recommended tighter controls on their medical use.
Historically, heroin has been a major opioid drug of abuse (Figure \(\PageIndex{5}\)). Heroin can be snorted, smoked, or injected intravenously. Like the stimulants described earlier, the use of heroin is associated with an initial feeling of euphoria followed by periods of agitation. Because heroin is often administered via intravenous injection, users often bear needle track marks on their arms and, like all abusers of intravenous drugs, have an increased risk for contraction of both tuberculosis and HIV.
Figure \(\PageIndex{5}\): (a) Common paraphernalia for heroin preparation and use are shown here in a needle exchange kit. (b) Heroin is cooked on a spoon over a candle. [(a) “Needle Exchange (brightened)” by Judy Schmitt is a derivative of “Needle Exchange” by Todd Huffman/Flickr, which is licensed under CC BY 2.0; (b) “Heroin” by Psychonaught/ Wikimedia Commons is in the public domain.]
Aside from their utility as analgesic drugs, opioid-like compounds are often found in cough suppressants, anti-nausea, and anti-diarrhea medications. Given that withdrawal from a drug often involves an experience opposite to the effect of the drug, it should be no surprise that opioid withdrawal resembles a severe case of the flu. While opioid withdrawal can be extremely unpleasant, it is not life-threatening (Julien, 2005). Still, people experiencing opioid withdrawal may be given methadone to make withdrawal from the drug less difficult. Methadone is a synthetic opioid that is less euphorigenic than heroin and similar drugs. Methadone clinics help people who previously struggled with opioid addiction manage withdrawal symptoms through the use of methadone. Other drugs, including the opioid buprenorphine, have also been used to alleviate symptoms of opiate withdrawal.
Codeine is an opioid with relatively low potency. It is often prescribed for minor pain, and it is available over-the-counter in some other countries. Like all opioids, codeine does have abuse potential. In fact, abuse of prescription opioid medications is becoming a major concern worldwide (Aquina et al., 2009; Casati et al., 2012).
Hallucinogens
A hallucinogen is one of a class of drugs that results in pro- found alterations in sensory and perceptual experiences (Figure \(\PageIndex{6}\)). In some cases, users experience vivid visual hallucinations. It is also common for this type of drug to cause hallucinations of body sensations (e.g., feeling as if you are a giant) and a skewed perception of the passage of time.
Figure \(\PageIndex{6}\): Psychedelic images like this are often associated with hallucinogenic compounds. [“Psychedelic Curl (rotated)” is a derivative of “psychedelic curl” by new 1lluminati/Flickr, which is licensed under CC BY 2.0.]
As a group, hallucinogens are incredibly varied in terms of the neurotransmitter systems they affect. Mescaline and LSD are serotonin agonists, and PCP (angel dust) and ketamine (an animal anesthetic) act as antagonists of the NMDA glutamate receptor. In general, these drugs are not thought to possess the same sort of abuse potential as other classes of drugs discussed in this section.
DIG DEEPER
Medical Marijuana
While the possession and use of marijuana is illegal in most states, it is now legal in Washington and Colorado to possess limited quantities of marijuana for recreational use (Figure \(\PageIndex{7}\)). In contrast, medical marijuana use is now legal in nearly half of the United States and in the District of Columbia. Medical marijuana is marijuana that is prescribed by a doctor for the treatment of a health condition. For example, people who undergo chemotherapy will often be prescribed marijuana to stimulate their appetites and prevent excessive weight loss resulting from the side effects of chemotherapy treatment. Marijuana may also have some promise in the treatment of a variety of medical conditions (Mather et al., 2013; Robson, 2014; Schicho & Storr, 2014).
Figure \(\PageIndex{7}\): Medical marijuana shops are becoming more and more common in the United States. [“IMG_7596” by Neeta Lind/Flickr is licensed under CC BY 2.0.]
While medical marijuana laws have been passed on a state-by-state basis, federal laws still classify this as an illicit substance, making conducting research on the potentially beneficial medicinal uses of marijuana problematic. There is quite a bit of controversy within the scientific community as to the extent to which marijuana might have medicinal benefits due to a lack of large-scale, controlled research (Bostwick, 2012). As a result, many scientists have urged the federal government to allow for relaxation of current marijuana laws and classifications in order to facilitate a more widespread study of the drug’s effects (Aggarwal et al., 2009; Bostwick, 2012; kogan & Mechoulam, 2007).
Until recently, the United States Department of Justice routinely arrested people involved and seized marijuana used in medicinal settings. In the latter part of 2013, however, the United States Department of Justice issued statements indicating that they would not continue to challenge state medical marijuana laws. This shift in policy may be in response to the scientific community’s recommendations and/or reflect changing public opinion regarding marijuana. ■
Aggarwal, S. K., Carter, G. T., Sullivan, M. D., ZumBrunnen, C., Morrill, R., & Mayer, J. D. (2009). Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions. Journal of Opioid Management, 5, 153–168. doi.org/10.5055/ jom.2009.0016
Aquina, C. T., Marques-Baptista, A., Bridgeman, P., & Merlin, M. A. (2009). Oxycontin® abuse and overdose. Postgraduate Medicine, 121, 163–167. https://doi.org/10.3810/pgm.2009.03.1988
Bostwick, J. M. (2012). Blurred boundaries: The therapeutics and politics of medical marijuana. Mayo Clinic Proceedings, 87, 172–186. https:// doi.org/10.1016/j.mayocp.2011.10.003
Casati, A., Sedefov, R., & Pfeiffer-Gerschel, T. (2012). Misuse of medicines in the European Union: A systematic review of the literature.
European Addiction Research, 18, 228–245. doi. org/10.1159/000337028
Cropley, M., Theadom, A., Pravettoni, G., & Webb, G. (2008). The effectiveness of smoking cessation interventions prior to surgery: A systematic review. Nicotine and Tobacco Research, 10, 407–412. https://doi.org/10.1080/14622200801888996
Fiorentini, A., Volonteri, L.S., Dragogna, F., Rovera, C., Maffini, M., Mauri, M. C., & Altamura, C. A. (2011). Substance-induced psychoses: A critical review of the literature. Current Drug Abuse Reviews, 4, 228–240. https://doi.org/10.2174/1874473711104040228
Haasen, C., & Krausz, M. (2001). Myths versus evidence with respect to cocaine and crack: Learning from the US experience. European Addiction Research, 7, 159–160. https://doi.org/10.1159/000050736
Herman, A., & Herman, A. P. (2013). Caffeine’s mechanisms of action and its cosmetic use. Skin Pharmacology and Physiology, 26, 8–14. https://doi.org/10.1159/000343174
Jayanthi, L. D., & Ramamoorthy, S. (2005). Regulation of monoamine transporters: Influence of psychostimulants and therapeutic antidepressants. The AAPS Journal, 7, E728–E738. https://doi.org/ 10.1208/aapsj070373
Julien, R. M. (2005). Opioid analgesics. In A primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs (10th ed., pp. 461–500). Worth.
Kogan, N. M., & Mechoulam, R. (2007). Cannabinoids in health and disease. Dialogues in Clinical Neuroscience, 9, 413–430. https:// www.ncbi.nlm.nih.gov/pubmed/18286801
Levitt, C., Shaw, E., Wong, S., & Kaczorowski, J. (2007). Systematic review of the literature on postpartum care: Effectiveness of interventions for smoking relapse prevention, cessation, and reduction in postpartum women. Birth, 34, 341–347. https://doi.org/ 10.1111/j.1523-536X.2007.00194.x
Mather, L. E., Rauwendaal, E. R., Moxham-Hall, V. L., & Wodak, A. D. (2013). (Re)introducing medicinal cannabis. The Medical Journal of Australia, 199, 759–761. doi.org/10.5694/mja13.10728
Maxwell, J. C. (2006). Trends in the abuse of prescription drugs. Gulf Coast Addiction Technology Transfer Center. https://attchub.org/ userfiles/file/GulfCoast/PrescriptionTrends_Web.pdf
McKim, W. A., & Hancock, S. D. (2013). Drugs and behavior: An introduction to behavioral pharmacology (7th ed.). Pearson.
Porkka-Heiskanen, T. (2011). Methylxanthines and sleep. Handbook of Experimental Pharmacology, 200, 331–348. doi.org/10.1007/ 978-3-642-13443-2_12
Reinerman, C. (2007, October 14). 5 myths about that demon crack. Washington Post. www.washingtonpost.com/wp-dyn/content/ article/2007/10/09/AR2007100900751.html
Robson, P. J. (2014). Therapeutic potential of cannabinoid medicines. Drug Testing and Analysis, 6, 24–30. doi.org/10.1002/dta.1529 Rothman, R. B., Blough, B. E., & Baumann, M. H. (2007). Dual dopamine/ serotonin releasers as potential medications for stimulant and alcohol addictions. The AAPS Journal, 9, E1–E10. https://doi.org/ 10.1007/978-0-387-76678-2_19
Schicho, R., & Storr, M. (2014). Cannabis finds its way into treatment of Crohn’s disease. Pharmacology, 93, 1–3. doi.org/10.1159/ 000356512
Shukla, R. K, Crump, J. L., & Chrisco, E. S. (2012). An evolving problem: Methamphetamine production and trafficking in the United States. International Journal of Drug Policy, 23, 426–435. https://doi.org/ 10.1016/j.drugpo.2012.07.004
Smedslund, G., Fisher, K. J., Boles, S. M., & Lichtenstein, E. (2004). The effectiveness of workplace smoking cessation programmes: A meta-analysis of recent studies. Tobacco Control, 13, 197–204. doi.org/10.1136/tc.2002.002915
U.S. Food and Drug Administration. (2013, October 24). Statement on proposed hydrocodone reclassification from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research. wayback. archive-it.org/7993/20170112130311/http://www.fda.gov/Drugs/ DrugSafety/ucm372089.htm
Wolk, B. J., Ganetsky, M., & Babu, K. M. (2012). Toxicity of energy drinks. Current Opinion in Pediatrics, 24, 243–251. doi.org/10.1097/ MOP.0b013e3283506827
